Marcel A Dammert

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 2

Top Topics

Dendritic Cells

Tyrosine Kinase

Top Venues

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lisa Werr, Dennis Plenker, Marcel A Dammert, Carina Lorenz, Johannes Brägelmann, Hannah L Tumbrink, Sebastian Klein, Anna Schmitt, Reinhard Büttner, Thorsten Persigehl, Kevan M Shokat, F Thomas Wunderlich, Alison M Schram, Martin Peifer, Martin L Sos, Hans Christian Reinhardt, Roman K Thomas
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Molecular cancer therapeutics 21 (5) (2022)
Johannes Brägelmann, Carina Lorenz, Sven Borchmann, Kazuya Nishii, Julia Wegner, Lydia Meder, Jenny Ostendorp, David F Ast, Alena Heimsoeth, Takamasa Nakasuka, Atsuko Hirabae, Sachi Okawa, Marcel A Dammert, Dennis Plenker, Sebastian Klein, Philipp Lohneis, Jianing Gu, Laura K Godfrey, Jan Forster, Marija Trajkovic-Arsic, Thomas Zillinger, Mareike Haarmann, Alexander Quaas, Stefanie Lennartz, Marcel Schmiel, Joshua D'Rozario, Emily S Thomas, Qi-Xiang Li, Clemens A Schmitt, Julie George, Roman K Thomas, Silvia von Karstedt, Gunther Hartmann, Reinhard Buttner, Roland T Ullrich, Jens Thomas Siveke, Kadoaki Ohashi, Martin Schlee, Martin L Sos
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature communications 12 (1) (2021)